Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is a hematologic malignancy.
• Relapsed and/or refractory MM poses treatment challenges.
• Current therapies often involve combination regimens.

Purpose of the Study:

• To evaluate the efficacy and safety of ixazomib in combination therapy for relapsed/refractory MM.
• To compare ixazomib-based triple therapy with placebo-based therapy.

Main Methods:

• The pivotal, global TOURMALINE-MM1 trial included adults with relapsed/refractory MM.
• Patients received ixazomib or placebo plus lenalidomide and dexamethasone.
• Progression-free survival (PFS) was the primary endpoint.

Main Results:

• Ixazomib significantly prolonged PFS compared to placebo.
• Improved time to progression and favorable PFS hazard ratios were observed across subgroups.
• Higher overall response rates were achieved with ixazomib.

Conclusions:

• Ixazomib plus lenalidomide and dexamethasone is an effective oral option for relapsed/refractory MM.
• The combination demonstrated a manageable safety profile.
• Ixazomib represents a novel oral proteasome inhibitor for MM treatment.